Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030
Viking Therapeutics (NASDAQ: VKTX) is positioning itself as a challenger in the obesity drug market, competing directly against industry titans Eli Lilly and Novo Nordisk. Both Eli Lilly and Novo…
Read the full articleYou might also wanna read
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and
Novo Nordisk loses global market lead to Eli Lilly outside the US
Novo Nordisk presses nu på endnu en afgørende flanke. Nye tal viser, at den danske medicinalgigant har mistet sit historiske forspring og ta
finans.dk·1mo agoJohnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.
Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical
As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal with Californian m
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
This biotech might have a bright future, but it'll need to survive against the incumbents to do so.
Comments
Sign in to join the conversation.
No comments yet. Be the first.